Trial Profile

A Phase 1, First in Human Study of TORL-4-500 in Patients with Advanced Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TORL 4 500 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Acronyms TRIO056
Sponsors TORL Biotherapeutics

Most Recent Events

10 Sep 2024 According to a TORL Biotherapeutics media release, company is actively enrolling patients in the escalation portion, part 1, assessing the safety, pharmacokinetics, biomarkers, and antitumor activity of TORL-4-500.
10 Apr 2024 According to a TORL BioTherapeutics media release, company announced $158M Series B-2 Financing led by Deep Track Capital.Proceeds from this Series B-2 financing will be used to continue the clinical development of this trial.
09 Jan 2024 According to a TORL Biotherapeutics media release, company is currently enrolling patients in the expansion portion of this phase 1 study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com